I'm LongbridgeAI, I can summarize articles.The Week
AstraZeneca fell 5.48% this week to close at $174.35, outperforming the S&P 500 by about 3.13 percentage points as the benchmark lost 8.61%. The move was a steady slide: shares opened Monday at $186.905 and drifted lower each day, touching a low of $174.03 on Friday with a weekly amplitude of 7.31%. Average daily volume was about 2.29m shares, roughly 20.75% below the 60-day median.
Key Events
The week was dense with regulatory and pipeline news. On Monday AstraZeneca secured FDA approval for an expanded Imfinzi combination in muscle-invasive bladder cancer, and received US and EU approvals for Klygefa in adults with generalised myasthenia gravis; Baxfendy was also recommended for approval in the EU. On Tuesday the company won a lawsuit over alleged Soliris monopoly claims. On Wednesday AstraZeneca announced a $200 million five-year commitment to Tempus AI, extending their partnership. On Thursday the FDA granted priority review to sonesitatug vedotin for second- and later-line treatment of advanced gastric cancer. The company also formed a new collaboration with the Lupus Research Alliance to advance drug development in lupus.
Analyst Ratings
Among 12 firms covering AstraZeneca, 7 rate it buy, 2 rate it over, 2 rate it hold, and 1 rates it sell; there are no under or no-opinion ratings. The consensus rating is buy, with a consensus target of $209.91, about 20.39% above the latest price. Individual targets range from $158 to $240, reflecting wide dispersion. Within its industry, the stock ranks 28th out of 207 pharmaceutical companies.
The Week Ahead
Macro data dominates Tuesday: FHFA house prices, the Case Shiller 20-city home price index, consumer confidence, and the Richmond Fed composite index. On the company side, the next earnings release is the 2026 fiscal fourth quarter report, scheduled for 9 February 2027 pre-market; consensus estimates put EPS at $1.735 and revenue at $16.6 billion.
In Short
AstraZeneca shares pulled back this week even as the pipeline news flow stayed heavy, and the consensus rating remains buy with a target roughly 20% above spot. At the same time, the stock trades around 24.5x earnings and 5.2x book, and the latest trading day showed net selling from both large and small players. The next question is whether this week’s regulatory wins translate into revenue momentum, and how macro data shapes valuation across the pharmaceutical space.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
